当前位置: 首页 >> 检索结果
3. Cardiac Resynchronization Therapy: A Review.
作者: Caique M Ternes.;Jitae A Kim.;Anirban Basu.;Kenneth A Ellenbogen.;Mihail G Chelu.
来源: JAMA. 2026年335卷20期1796-1807页
Heart failure (HF) affects more than 64 million individuals worldwide, and acute HF is associated with 1-year mortality rates of 23.6% in North America and Europe. Cardiac dyssynchrony from conduction system disease may cause HF progression, particularly in patients with left ventricular (LV) systolic dysfunction.
5. Long-Term Cognitive Ability and Academic Achievement After Childhood Severe Malaria.
作者: Paul Bangirana.;Kagan A Mellencamp.;Jie Ren.;Jacqueline A Nakitende.;Andrea L Conroy.;Dibyadyuti Datta.;Christian Kautzman.;Michael J Goings.;Robert O Opoka.;Ruth Namazzi.;Bjarne Robberstad.;Richard Idro.;Chandy C John.
来源: JAMA. 2026年335卷18期1596-1605页
Cerebral malaria and severe malarial anemia are associated with cognitive impairment and decreased academic achievement 1 to 2 years after the initial episode. The extent to which impairment persists into later childhood and adolescence is unknown.
10. Changes in Clinician Time Expenditure and Visit Quantity With Adoption of Artificial Intelligence-Powered Scribes: A Multisite Study.
作者: Lisa S Rotenstein.;A Jay Holmgren.;Robert Thombley.;Aditi Sriram.;Reema H Dbouk.;Melissa Jost.;Debbie Aizenberg.;Scott MacDonald.;Naga Kanaparthy.;Brian Williams.;Allen Hsiao.;Lee Schwamm.;Sara Murray.;Maria Byron.;Jacqueline G You.;Amanda J Centi.;Christine Iannaccone.;Michelle Frits.;Adam B Landman.;Karandeep Singh.;Ming Tai-Seale.;Jie Cao.;Katharine Lawrence.;Devin Mann.;Christopher Holland.;Bryan Blanchette.;Jesse Ehrenfeld.;Edward R Melnick.;David W Bates.;Julia Adler-Milstein.;Rebecca G Mishuris.
来源: JAMA. 2026年335卷16期1408-1417页
Artificial intelligence (AI)-enabled scribes have been proposed to reduce electronic health record (EHR) burden and improve clinician satisfaction. There is limited evidence about their associated results across multiple sites and relative benefits for different clinician groups.
15. Hospital Adoption and Pricing for Oncology Biosimilars.
Many physician-administered oncology biologics are losing patent protection in the coming years and will face competition from biosimilars. Hospitals and insurers share a mutual interest in developing payment methods that share the potential savings from adopting these less costly agents.
16. Changes in Organ Donation After Circulatory Death in the United States.
作者: Syed Ali Husain.;Jennifer D Motter.;Darren Stewart.;Macey L Levan.;Sunjae Bae.;Brendan Parent.;Bonnie E Lonze.;Philip M Sommer.;Sommer E Gentry.;Jeffrey M Stern.;Allan B Massie.;Dorry L Segev.;Babak J Orandi.
来源: JAMA. 2026年335卷12期1087-1089页 20. Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial.
作者: Gail D'Onofrio.;Andrew A Herring.;Kathryn F Hawk.;Jeanmarie Perrone.;Ethan Cowan.;Ryan P McCormack.;James Dziura.;Abigail G Matthews.;Michael V Pantalon.;Patricia Owens.;Shara Martel.;Edouard Coupet.;Michele R Lofwall.;Sharon L Walsh.;E Jennifer Edelman.;Joseph E Carpenter.;Tania D Strout.;Michael R Baumann.;Erik Anderson.;Tyler W Barrett.;Alyrene Dorey.;Peter Taillac.;Gerald Cochran.;Cameron S Crandall.;Jason Wilson.;Jacob Manteuffel.;Jon B Cole.;Lauren K Whiteside.;Christopher Jones.;Elizabeth Samuels.;Kristen Huntley.;David A Fiellin.; .
来源: JAMA. 2026年335卷11期948-960页
Extended-release injectable buprenorphine may expand the reach of initiating medications for opioid use disorder in high-risk and hard-to-reach individuals who visit the emergency department (ED) and can be administered in low levels of withdrawal.
|